Lundbeck presents positive results from migraine drug trial

New data from a study of Lundbeck's migraine drug Vyepti shows a significant effect on patients who have been through two to four prior failed treatments with other types of migraine drugs.
Photo: Jens Dresling
Photo: Jens Dresling
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED DANIEL PEDERSEN

Both primary and secondary endpoints were met in Lundbeck's phase IIIb trial, which goes under the name Deliver, of the migraine drug Vyepti, it reports in a press release on Monday morning.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading